Optiver Holding
CRNX icon

Optiver Holding’s Crinetics Pharmaceuticals CRNX Stock Holding History

Optiver Holding’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.1K Sell
113
-53
-32% -$2.37K ﹤0.01% 1509
2025
Q4 		$7.73K Sell
166
-100
-38% -$4.45K ﹤0.01% 1203
2025
Q3 		$11.1K Sell
266
-102
-28% -$3.26K ﹤0.01% 1229
2025
Q2 		$10.6K Buy
368
+191
+108% +$5.9K ﹤0.01% 987
2025
Q1 		$5.94K Buy
+177
New +$6.61K ﹤0.01% 1050

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Optiver Holding's CRNX Position: Q1 2026 in Review

Optiver Holding reduced its Crinetics Pharmaceuticals (CRNX) stake by 32% in Q1 2026, selling an estimated $2.37K and leaving 113 shares worth $4.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1509.

Optiver Holding first reported a position in CRNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $11.1K in Q3 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Optiver Holding held 113 shares of Crinetics Pharmaceuticals worth $4.1K as of Q1 2026.
  • Optiver Holding sold 53 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $2.37K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1509 holding.
  • Optiver Holding first reported a position in Crinetics Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Optiver Holding's Crinetics Pharmaceuticals position peaked at $11.1K in Q3 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.